Eprosartan - A review of its use in the management of hypertension

被引:23
作者
Robbins, GW [1 ]
Scott, LJ [1 ]
机构
[1] Adis Int Ltd, Auckland 1311, New Zealand
关键词
D O I
10.2165/00003495-200565160-00012
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Sources: Medical literature published in any language since 1980 on eprosartan, identified using MEDLINE and EMBASE, supplemented by AdisBase (a proprietary database of Adis International). Additional references were identified from the reference lists of published articles. Bibliographical information, including contributory unpublished data, was also requested from the company developing the drug. Search strategy: MEDLINE search terms were 'eprosartan' or 'SKF-108566' and ('hypertension' or 'antihypertensive'). EMBASE and AdisBase search terms were 'eprosartan' and ('hypertension' or 'antihypertensive'). Searches were last updated 15 October 2005. Selection: Studies in patients with hypertension who received eprosartan. Inclusion of studies was based mainly on the methods section of the trials. When available, large, well controlled trials with appropriate statistical methodology were preferred. Relevant pharmacodynamic and pharmacokinetic data are also included.
引用
收藏
页码:2355 / 2377
页数:23
相关论文
共 81 条
[1]   CHARACTERIZATION OF [H-3] SK-AND-F-108566 AS A RADIOLIGAND FOR ANGIOTENSIN TYPE-1 RECEPTOR [J].
AIYAR, N ;
GRIFFIN, E ;
SHU, A ;
HEYS, R ;
BERGSMA, DJ ;
WEINSTOCK, J ;
EDWARDS, R .
JOURNAL OF RECEPTOR RESEARCH, 1993, 13 (05) :849-861
[2]  
Antonopoulos S, 2003, J HYPERTENS, V21, pS133
[3]  
Aranda P, 2003, J HYPERTENS, V21, pS66
[4]   Haemodynamic effects of eprosartan and valsartan in hypertensive patients during isometric and mental stress [J].
Arosio, E ;
De Marchi, S ;
Prior, M ;
Rigoni, A ;
Lechi, A .
JOURNAL OF HYPERTENSION, 2005, 23 (10) :1923-1927
[5]   Inhibition of facilitation of sympathetic neurotransmission and angiotensin II-induced pressor effects in the pithed rat: comparison between valsartan, candesartan, eprosartan and embusartan [J].
Balt, JC ;
Mathy, MJ ;
Pfaffendorf, M ;
van Zwieten, PA .
JOURNAL OF HYPERTENSION, 2001, 19 (12) :2241-2250
[6]   Eprosartan reduces cardiac hypertrophy, protects heart and kidney, and prevents early mortality in severely hypertensive stroke-prone rats [J].
Barone, FC ;
Coatney, RW ;
Chandra, S ;
Sarkar, SK ;
Nelson, AH ;
Contino, LC ;
Brooks, DP ;
Campbell, WG ;
Ohlstein, EH ;
Willette, RN .
CARDIOVASCULAR RESEARCH, 2001, 50 (03) :525-537
[7]   Eprosartan improves cardiac performance, reduces cardiac hypertrophy and mortality and downregulates myocardial monocyte chemoattractant protein-1 and inflammation in hypertensive heart disease [J].
Behr, TM ;
Willette, RN ;
Coatney, RW ;
Berova, M ;
Angermann, CE ;
Anderson, K ;
Sackner-Bernstein, JD ;
Barone, FC .
JOURNAL OF HYPERTENSION, 2004, 22 (03) :583-592
[8]   A review of eprosartan pharmacokinetic and pharmacodynamic drug interaction studies [J].
Blum, RA ;
Kazierad, DJ ;
Tenero, DM .
PHARMACOTHERAPY, 1999, 19 (04) :79S-85S
[9]  
*BOEHR ING GMBH, TELM RAND ASS STUDY
[10]   Comparison of quality of life and cough on eprosartan and enalapril in people with moderate hypertension [J].
Breeze, E ;
Rake, EC ;
Donoghue, MD ;
Fletcher, AE .
JOURNAL OF HUMAN HYPERTENSION, 2001, 15 (12) :857-862